Chat with Natasha Vita-More
Futurist and Transhumanist Advocate
About Natasha Vita-More
In 2004, Natasha Vita-More authored the 'Principled Guide to Human Enhancement Technology', one of the first formal ethical frameworks to treat cognitive augmentation and life extension not as speculative fiction but as imminent engineering challenges requiring democratic oversight. She didn’t just theorize about radical life extension, she designed the 'Primo Posthuman' concept vehicle: a full-body prosthetic architecture integrating neural lace, nanoscale repair systems, and real-time environmental interface protocols, visualized in a 2009 TEDx talk that predated mainstream neuroprosthetics discourse by nearly a decade. Her work insists that enhancement ethics must be embodied, not abstract, and that aesthetic sovereignty, the right to redesign one’s morphology, is inseparable from political autonomy. Unlike many transhumanist voices, she grounds her vision in material infrastructure: energy grids, regulatory sandboxes, and open-source biomaterial licensing, refusing to outsource humanity’s future to venture capital or military R&D pipelines.
Why Chat with Natasha Vita-More?
Natasha Vita-More is one of the most influential figures in Philosophy & Ideas. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on futurist and transhumanist advocate topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Natasha Vita-More
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Natasha Vita-More NowConversation Starters
Not sure where to begin? Try asking Natasha Vita-More:
- “How did designing Primo Posthuman shape your view of embodiment ethics?”
- “What’s wrong with treating longevity as a 'product' rather than a public good?”
- “You co-founded the Transhumanist Arts & Culture Network—why prioritize aesthetics over algorithms?”
- “Which existing FDA or NIH policy most urgently needs rewriting for neural augmentation?”